Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupdel(17p), TP 53 mutationunfitICD10C82.-C82.7C82.9C83.0C83.1C83.3C83.7C88.0-C91.0-C91.1-MeSHLymphoma, B-Cell, Marginal ZoneLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceACAL/OBIN/VNTC: ACAL100, CLL, C1, var. 1 (PID2282) -|- C2 (PID2283) -|- C3 (PID2284) -|- C4 (PID2285) -|- C5-7 (PID2286) -|- C8+ (PID2287)ALEM(3/10/30), CLL (PID333) -|- ALEM30 (PID334)BOVen: OBIN(100/900/1000)/ZANU160, CLL, C1 (PID2637) -|- C2 (PID2638) -|- C3 (PID2639) -|- C4-8 (PID2640) -|- C9+ (PID2641)CAPTIVATE (IBRU/VNTC): CLL, first-line, Z1-3 (PID1267) -|- Z4 (PID1236) -|- Z5-15 (PID1268)CHLO(0.4-0.7), CLL, C1-4 (PID320) -|- CHLO0.8, C5+ (PID868)COMPLEMENT 1: OFAT(300/1000)/CHLO10, CLL C1 (PID407) -|- OFAT1000/CHLO10, C2+ (PID408)ELEVATE TN: ACAL100, CLL, C1 (PID1654) -|- C2 (PID1655) -|- C3-7 (PID1656) -|- (PID1653)FCR (RITU375/FLUD25/CYCL250), CLL, first-line C1 (PID317) -|- FCR (RITU500/FLUD25/CYCL250), C2-6 (PID318)FLAIR (IBRU/VNTC): IBRU420, CLL, first-line, C1-2, var. 1 (PID2599) -|- C3 (PID2600) -|- C4+ (PID2601)GAUSS: OBIN1000, B-NHL, Ind. (PID2340) -|- OBIN1000, B-NHL, maint. (PID2341)GIVe (OBIN/IBRU/VNTC), CLLHELIOS: IBRU420/RITU375/BEND70, CLL, C1 (PID119) -|- C2+ (PID1179) -|- maint. (PID82)IBRU420, CLL, C1 (PID1328) -|- C2 (PID1326) -|- C3-7 (PID1327) -|- maint. (PID1328)IDEL150/RITU375, CLL C1 (PID276) -|- C2-5 (PID330) -|- C6-8 (PID331)iFCR (IBRU420/RITU375/FLUD25/CYCL250), CLL, first-line, C1 (PID1546) -|- iFCR (IBRU420/RITU500/FLUD25/CYCL250), C2-6 (PID1547)iLLUMINATE: IBRU420/OBIN(100/900/1000), CLL, first-line, C1 (PID1339) -|- IBRU420/OBIN(1000), C2-6 (PID1340)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)OBIN(100/900/1000)/CHLO0.5, CLL C1 (PID323) -|- OBIN1000/CHLO0.5, C2-6 (PID335)OBIN(100/900/1000)/VNTC20, CLL, C1, first-line (PID1259) -|- C2 (PID1316) -|- C3-6 (PID1317) -|- maint. (PID1318)OFAT(300/1000)/BEND90, CLL C1 (PID431) -|- OFAT1000/BEND90, C2+ (PID432)R-BENDA (RITU375/BEND70), CLL, second line, C1 (PID574) -|- R-BENDA (RITU500/BEND70), C2-6 (PID683)R-BENDA (RITU375/BEND90), CLL, first-line, C1 (PID315) -|- R-BENDA (RITU500/BEND90), C2-6 (PID316)RITU375/CHLO10, CLL C1 (PID321) -|- RITU500/CHLO10, C2-6 (PID322)RITU375/LENA20, ind. B-NHL ind. (PID309) -|- LENA20 maint. (PID329)RITU375/VNTC(20/50/100/200/400), CLL, C1 (PID1148) -|- C2 (PID1149) -|- C3-7 (PID1150) -|- maint. (PID1151)STUDY - CLL2-BAG: OBIN1000/VNTC400 - OBIN(100/900/1000), CLL, Ind. C1 (PID609) -|- C2 (PID613) -|- C3-6 (PID624) -|- maint. (PID633)STUDY-CLL13-GVe: OBIN(100/900/1000)/VNTC20, CLL, C1 (PID1144) -|- C2 (PID1145) -|- C3-6 (PID1146) -|- C7-12 (PID1147)STUDY-CLL13-RVe: RITU375/VNTC20, CLL, C1 (PID1196) -|- C2 (PID1197) -|- C3-6 (PID1198) -|- C7-12 (PID1147)Study-CLL17-OBIN(100/900/1000)/VNTC20, CLL, C1 (PID1854) -|- C2 (PID1855) -|- C3-6 (PID1856) -|- C7-12 (PID1857)VNTC(20/50/100/200), CLL, C1 (PID854) -|- VNTC400, C2+ (PID855)ChemotherapyChemo-substanceAcalabrutinibAlemtuzumabBendamustineChlorambucilCyclophosphamideFludarabineIbrutinibIdelalisibLenalidomideObinutuzumabOfatumumabRituximabVenetoclaxZanubrutinibChemo-substanceAcalabrutinibAlemtuzumabBendamustineChlorambucilCyclophosphamideFludarabineIbrutinibIdelalisibLenalidomideObinutuzumabOfatumumabRituximabVenetoclaxZanubrutinibChemo-substanceAcalabrutinibAlemtuzumabBendamustineChlorambucilCyclophosphamideFludarabineIbrutinibIdelalisibLenalidomideObinutuzumabOfatumumabRituximabVenetoclaxZanubrutinibChemo-substanceAcalabrutinibAlemtuzumabBendamustineChlorambucilCyclophosphamideFludarabineIbrutinibIdelalisibLenalidomideObinutuzumabOfatumumabRituximabVenetoclaxZanubrutinibNo. Substances1234 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneRasburicaseSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneRasburicaseSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneRasburicaseSupportive substanceAcetylsalicylic acidAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCimetidineCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronPantoprazoleParacetamolPegfilgrastimPrednisoloneRasburicaseNo. Substances12345678910Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceReinductionTherapy intentiondisease controlpalliativeRisksAllergic ReactionAnemia Hb below 8g/dlArthalgiaAtrial FibrillationBleedingCardiotoxicityCMV Infection (asympt. + sympt.)ConstipationDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheHemorrhageHyperglycemiaHyperkalemiaHypertensionHypocalcemiaHyponatremiaHypophosphatemiaIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMyalgiasNeurotoxicityNeutropeniaPneumoniaPyrexiaRenal FailureSepsisThrombocytopenia below 50 000/µlTumor Lysis SyndromeUpper Respiratory Tract InfectionVomiting only studiesPublicationAuthorAl-Sawaf OArdeshna KMBrown JRBurger JByrd JCCramer PCzuczman MSDavids MSDavies AEichhorst BEichhorst BFFischer KFraser GFurmanGhia PGoede VHallek MHillmenHillmen PHuber HKnauf WULiu E Moreno CMunir TOffner FRobinson KSRummel MJSehn LHSeymour JShanafelt TDSharman J PSoumerai JDStilgenbauer STam CSTuscano JMDiseaseaktive, unbehandelte CLL, mit Behandlungsindikation, ungeeignet für Chemoimmuntherapie oder ≤60 Jahre, ECOG 0-2aktive, unbehandelte CLL, mit Behandlungsindikation, ungeeignet für Chemoimmuntherapie oder ≥ 65 Jahre, ECOG 0-2B-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieCD20-positives indolentes B-Non-Hodgkin-Lymphom, rezidiviert oder therapierefraktär, nach mindestens 1 rituximabhaltiger Therapie, ECOG 0-2Chronische lymphatische Leukämie, CD20+, ErstlinieChronische lymphatische Leukämie, ErstlinieChronische lymphatische Leukämie, Erstlinie, > 64 Jahre, ECOG: 0-2Chronische lymphatische Leukämie, Erstlinie, del(17p) und/oder TP53 MutationCLL, Erstline bei Patienten ohne Eignung für Fludarabin, Zweitlinie bei RezidivCLL, Erstlinie, ECOG 0-2CLL, Erstlinie, ECOG 0-2 CLL, Erstlinie, ECOG 0-2, älter als 65 J (oder älter als 18 und Kreatinin-Clearance von 30–69 ml/min oder CIRS größer 6)CLL, Rezidiv, Progress innerhalb von 24 Monaten nach letzter Therapie, nicht Chemotherapie geeignet CIRS mindestens 6, CD20 Antikörper-Therapie oder 2 frühere ChemotherapienCLL, rezidiviert oder therapierefraktär, ECOG 0-2CLL, Rezidiv oder refraktär, ECOG 0-2CLL, therapiebedürftig nach iwCLL 2008-Kriterien, Patientenalter 18-65 Jahre, ECOG 0-1CLL mit Behandlungsindikation, ECOG 0-2, ErstlinieCLL mit Behandlungsindikation, Erstlinie, aufgrund Alter oder AZ Kontraindikation gegen Fludarabin-basierte TherapieCLL mit Behandlungsindikation, Erstlinie, ECOG 0-1, geringe Komorbiditäten CLL mit Behandlungsindikation, Erstlinie, ECOG 0-2CLL mit Behandlungsindikation, Erstlinie, ECOG 0-2, Patienten zwischen 65 und 80 Jahre altCLL mit Behandlungsindikation, Erstlinie, relevante Komorbidität (CIRS-Score >6 oder KreaClearance zwischen 30 und 69 ml/min)CLL oder SLL, Erstlinie, > 65 Jahre, ECOG 0-2CLL oder SLL, mindestens eine VortherapieCLL Stadium B und C mit Behandlungsindikation, Erstlinie, ECOG 0-2CLL Std. B und C mit Behandlungsindikation, Erstlinie, ECOG 0-2Foll. L. °I-II, Marginalzonen-L., kleines lymphozyt. L., ECOG 0-2, mind. eine Vortherapiefoll. L. °I-II, Marginalzonen-L., kleines lymphozyt. Lymphom, mind. eine Vortherapie, ECOG 0-2Follikuläres Lymphom, kleines lymphozytische Lymphom, Erst- bis Fünftlinie, Karnofsky-Index größer 60%MCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieNon-Hodgkin Lymphom, low-grade, nicht-aggressiv, Stadium III-IVrefraktäre/rezidivierende CLL/SLL ohne Deletion p17, ECOG 0-1rezidivierende oder refraktäre chronisch lymphatische Leukämie, 1-3 Vortherapien, ECOG 0-1rezidivierende oder refraktäre CLL, del17p, ECOG 0-2 Rezidivierte oder refraktäre CLLunbehandelte chronische lymphatische Leukämie, ≤70 Jahre, ECOG 0-2Wiederkehrende, refraktäre CLL, 2.-4. Linie, ECOG 0-1Wiederkehrende, refraktäre CLL, 2.-4. Linie, ECOG 0-2OriginAbteilung für Hämatologie/Onkologie, Onkologische Praxis Frankfurt, DeutschlandBritish National Lymphoma Investigation, CRC and UCL Cancer Trials Centre, London, UKCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCentre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, GAUSS Study CLL14 trial, Department I of Internal Medicine, Center of Integrated Oncology, University Hospital of CologneCologne University Hospital, Cologne, GermanyDana-Farber Cancer Institute, Boston, ALPINE trialDana-Farber Cancer Institute, Boston, MA, USADana-Farber Cancer Institute, Boston, USADCLLSG, HOVON, SAKK, GAIA trialDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, VictoriaDepartment of Haematology, St Jame's University Hospital, Leeds, United KingdomDepartment of Haematology, St Jame's University Hospital, Leeds, United Kingdom, COMPLEMENT 1Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, iLLUMINATEDepartment of Hematology, Internal Medicine, Pathology, Ohio State University, Columbus, RESONATE trialDepartment of Leukemia, MD Anderson Cancer Center, Houston, RESONATE-2Division of Hematology, Department of Medicine, Stanford University School of MedicineGerman Chronic Lymphocytic Leukemia Study Group (GCLLSG)Internal Medicine III, Ulm University, Ulm, GermanyJuravinski Cancer Centre, McMaster University, Hamilton, ON, Canada, HELIOSLeeds Cancer Research UK Clinical Trials Unit, United Kingdom, FLAIR trialLeeds Teaching Hospitals National Health Service Trust, Leeds, United KingdomMassachusetts General Hospital Cancer Center, Boston, USAPeter MacCallum Cancer Center, Melbourne, VIC, Australia, CAPTIVATE trialQE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaRoswell Park Cancer Institute, Buffallo, NY, USAStudy Group indolent Lymphomas (StiL)The German Chronic Lymphocytic Leukaemia Study Group (GCLLSG)The German Chronic Lymphocytic Leukaemia Study Group (GCLLSG), and international investigatorsUC Davis Cancer Center, Sacramento, USAUniversitair Ziekenhuis Gent, Gent, BelgienUniversita Vita-Salute San Raffaele, Milano, ItalyUniversity Hospital Cologne, DCLLSG-Studiengruppe, CLL-2-BAGUniversity of Texas M.D. Anderson Cancer Center, HoustonUniversitätsklinikum Ulm, Ulm, GermanyWeill Cornell Medical College New YorkWillamette Valley Cancer Institute/US Oncology, Eugene, USA, ELEVATE TNProtocols in Revision 97 protocols foundProtocols under revision.Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2 (PID1655)Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2, Variant 1. (PID2283)Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax (20/50/100/200/400), Chronic Lymphocytic Leukemia, Cycle 4. (PID2285)Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 5-7. (PID2286)Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3, Variant 1 (PID2284)Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3-7 (PID1656)Acalabrutinib 100 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 8+ (PID2287)Acalabrutinib 100, Chronic Lymphocytic Leukemia (PID1653)Acalabrutinib 100, Chronic Lymphocytic Leukemia, second line (PID1657)Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1 (PID1654)Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1, Variant 1 (PID2282)Alemtuzumab 3/10/30, Chronic Lymphocytic Leukemia (PID333)Alemtuzumab 30, Chronic Lymphocytic Leukemia (PID334)Bendamustine 100, Chronic Lymphocytic Leukemia (PID319)Chlorambucil (0.4-0.7), Chronic Lymphocytic Leukemia, cycle 1-4 (PID320)Chlorambucil 0.8, Chronic Lymphocytic Leukemia, cycle 5+ (PID868)Chlorambucil 10, B-Non-Hodgkin Lymphoma (PID2334)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471)Ibrutinib 420 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, first-line, cycle 2-6 (PID1340)Ibrutinib 420 / Obinutuzumab(100/900/1000), Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID1339)Ibrutinib 420 / Rituximab (50,325), Chronic Lymphocytic Leukemia, cycle 2, first-line (PID1326)Ibrutinib 420 / Rituximab 375 / Bendamustine 70, Chronic Lymphocytic Leukemia, cycle 1 (PID119)Ibrutinib 420 / Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID1546)Ibrutinib 420 / Rituximab 500 / Bendamustine 70, Chronic Lymphocytic Leukemia, cycle 2+ (PID1179)Ibrutinib 420 / Rituximab 500, Chronic Lymphocytic Leukemia, cycle 3-7, first-line (PID1327)Ibrutinib 420 / Rituximab 500/ Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemiaa, first-line, cycle 2-6 (PID1547)Ibrutinib 420 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, first-line, cycle 3, variant 1 (PID2600)Ibrutinib 420 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, first-line, cycle 4 (PID1236)Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, first-line, cycle 4+, variant 1 (PID2601)Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, first-line, cycle 5-15. (PID1268)Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 7-12 (PID2280)Ibrutinib 420, Chronic Lymphocytic Leukemia, first-line (PID790)Ibrutinib 420, Chronic Lymphocytic Leukemia, first-line, cycle 1-2, variant 1 (PID2599)Ibrutinib 420, Chronic Lymphocytic Leukemia, first-line, cycle 1-3. (PID1267)Ibrutinib 420, Chronic Lymphocytic Leukemia, second line (PID332)Ibrutinib 420, Chronic Lymphocytic Leukemia, cycle 1 and maintenance, first-line (PID1328)Ibrutinib 420, Chronic Lymphocytic Leukemia, Cycle 13-36 (PID2281)Ibrutinib 420, CLL, maintenance (PID82)Idelalisib 150 / Rituximab 375, Chronic Lymphocytic Leukemia, cycle 1 (PID276)Idelalisib 150 / Rituximab 500, Chronic Lymphocytic Leukemia, cycle 2-5 (PID330)Idelalisib 150 / Rituximab 500, Chronic Lymphocytic Leukemia, cycle 6-8 (PID331)Obinutuzumab (100/900/1000) / Chlorambucil 0.5, CLL Cycle 1 (PID323)Obinutuzumab (100/900/1000) / Ibrutinib 420 / Venetoclax 20, Chronic Lymphocytic Leukemia, Cycle 1 (PID2277)Obinutuzumab (100/900/1000) / Venetoclax 20, Chronic Lymphocytic Leukemia, cycle 1, first-line (PID1259)Obinutuzumab (100/900/1000) / Zanubrutinib 160, Chronic Lymphocytic Leukemia, Cycle 1 (PID2637)Obinutuzumab 1000 / Chlorambucil 0.5, CLL Cycle 2-6 (PID335)Obinutuzumab 1000 / Ibrutinib 420 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, Cycle 2 (PID2278)Obinutuzumab 1000 / Ibrutinib 420 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 3-6 (PID2279)Obinutuzumab 1000 / Venetoclax (20/50/100/200), CLL, Induction Cycle 2 (PID613)Obinutuzumab 1000 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, cycle 2, first line (PID1316)Obinutuzumab 1000 / Venetoclax 400 - Obinutuzumab (100/900/1000), CLL, Induction Cycle 1 (PID609)Obinutuzumab 1000 / Venetoclax 400 - Venetoclax 400, Chronic Lymphocytic Leukemia, maintenance, first-line (PID1318)Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 3-6, first line (PID1317)Obinutuzumab 1000 / Venetoclax 400, CLL, maintenance (PID633)Obinutuzumab 1000 / Venetoclax 400, CLL, Induction, Cycle 3-6 (PID624)Obinutuzumab 1000 / Zanubrutinib 160 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, Cycle 3 (PID2639)Obinutuzumab 1000 / Zanubrutinib 160 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 4-8 (PID2640)Obinutuzumab 1000 / Zanubrutinib 160, Chronic Lymphocytic Leukemia, Cycle 2 (PID2638)Obinutuzumab 1000, B-non-Hodgkin Lymphoma, maintenance (PID2341)Obinutuzumab 1000, B-Non-Hodgkin Lymphoma, Induction (PID2340)Ofatumumab (300/1000) / Bendamustine 90, Chronic Lymphocytic Leukemia, cycle 1 (PID431)Ofatumumab (300/1000) / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 1 (PID407)Ofatumumab 1000 / Bendamustine 90, Chronic Lymphocytic Leukemia, cycle 2+ (PID432)Ofatumumab 1000 / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 2+ (PID408)RITU375/FLUD25, follicular lymphoma and indolent B-NHL (PID304)Rituximab 1400, single dose subcutaneous (PID310)Rituximab 375 / Bendamustine 70, Chronic Lymphocytic Leukemia, second line, cycle 1 (PID574)Rituximab 375 / Bendamustine 90, Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID315)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270)Rituximab 375 / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 1 (PID321)Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemia, first-line, cycle 1 (PID317)Rituximab 375 / lenalidomide 20 - Lenalidomide 20 maintenance, indolent B non-Hodgkin Lymphoma induction (PID329)Rituximab 375 / Lenalidomide 20, indolent B non-Hodgkin Lymphoma, induction (PID309)Rituximab 375 / Venetoclax (20/50/100/200/400), Chronic Lymphocytic Leukemia, cycle 1 (PID1148)Rituximab 375 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 2 (PID1149)Rituximab 500 / Bendamustine 70, Chronic Lymphocytic Leukemia, second-line, cycle 2-6 (PID683)Rituximab 500 / bendamustine 90, Chronic Lymphocytic Leukemia, first-line, cycle 2-6 (PID316)Rituximab 500 / Chlorambucil 10, Chronic Lymphocytic Leukemia, cycle 2-6 (PID322)Rituximab 500 / Fludarabine 25 / Cyclophosphamide 250, Chronic Lymphocytic Leukemia, first-line, cycle 2-6 (PID318)Rituximab 500 / Venetoclax 400 - Venetoclax 400, Chronic Lymphocytic Leukemia, maintenance (PID1151)Rituximab 500 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 3-7 (PID1150)Study - CLL13 - GVe - Obinutuzumab (100/900/1000) / Venetoclax 20, Chronic Lymphocytic Leukemia, Cycle 1 (PID1144)Study - CLL13 - GVe - Obinutuzumab 1000 / Venetoclax (50/100/200/400), CLL, Cycle 2 (PID1145)Study - CLL13 - GVe - Obinutuzumab 1000 / Venetoclax 400, CLL, Cycle 3-6 (PID1146)Study - CLL13 - GVe/RVe - Venetoclax 400, CLL, cycle 7-12, maintenance (PID1147)Study - CLL13 - RVe - Rituximab 375 / Venetoclax 20, Chronic Lymphocytic Leukemia, cycle 1 (PID1196)Study - CLL13 - RVe - Rituximab 500 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, cycle 2 (PID1197)Study - CLL13 - RVe - Rituximab 500 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 3-6 (PID1198)Study - CLL17 - Obinutuzumab (100/900/1000) / Venetoclax 20, Chronic Lymphocytic Leukemia, cycle 1 (PID1854)Study - CLL17 - Obinutuzumab 1000 / Venetoclax (50/100/200/400), Chronic Lymphocytic Leukemia, cycle 2 (PID1855)Study - CLL17 - Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 3-6 (PID1856)Study - CLL17 - Venetoclax 400, Chronic Lymphocytic Leukemia, cycle 7-12 (PID1857)Venetoclax 20/50/100/200, Chronic Lymphocytic Leukemia, cycle 1 (PID854)Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 2+ (PID855)Zanubrutinib 160 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 9+ (PID2641)Zanubrutinib 160, Chronic Lymphocytic Leukemia (PID2225)
